Where is Surgerii Robotics headquartered?

Surgerii Robotics is headquartered in Beijing, China.

What does Surgerii Robotics do?

Surgerii Robotics operates in the Robotics / Embodied AI sector. Developer of the SHURUI single-port surgical robot with snake-like nitinol instruments enabling minimally invasive laparoscopic surgery through a single ~1.8cm incision. Enables highly complex, precise single-port surgical procedures via a proprietary 'Dual Continuum Mechanism' that reduces invasiveness versus multi-port robotic systems while covering a broader patient population, including pediatric cases.

When was Surgerii Robotics founded?

Surgerii Robotics was founded in 2014. It is based in Beijing, China.

Who is the CEO of Surgerii Robotics?

Kai Xu (Prof. Xu Kai) is the CEO of Surgerii Robotics. The company was founded in 2014.

Where is Surgerii Robotics located?

Surgerii Robotics is headquartered in Beijing, China.

What funding stage is Surgerii Robotics at?

Surgerii Robotics is currently at the Growth Stage stage.

Surgerii Robotics

Category: Robotics / Embodied AI

Developer of the SHURUI single-port surgical robot with snake-like nitinol instruments enabling minimally invasive laparoscopic surgery through a single ~1.8cm incision. Surgerii Robotics was founded in 2014. The company is led by Kai Xu (Prof. Xu Kai). Based in Beijing, China. Total funding raised: $275M. Latest round: Series D. Key investors include Loyal Valley Capital, Shanghai Healthcare Capital, V Star Capital, DNV Capital, Hefei Industrial Investment, Shunwei Capital, SDIC Fund, Tianfeng Capital, Medtronic, Hyfinity Investments, CD Capital, NNFE.

Founded: 2014
Headquarters: Beijing, China
Total funding: $275M

Value proposition

Enables highly complex, precise single-port surgical procedures via a proprietary 'Dual Continuum Mechanism' that reduces invasiveness versus multi-port robotic systems while covering a broader patient population, including pediatric cases.

Products and solutions

SHURUI Single-Port Surgical Robot (SR-ENS-600) with snake-like surgical instruments, SHURUI SR-ENS-660 (upgraded model, NMPA approved Mar 2026), modular robotic platform

Unique value

Only single-port surgical robot with CE certification approved for pediatric use; first Chinese surgical robot certified across all patient age groups; first single-port endoscopic surgical robot approved by China's NMPA (2023).

Target customer

Grade A tertiary hospitals and surgical departments (urology, gynecology, general surgery, thoracic surgery) in China and internationally (Europe focus).

Industries served

AI in Healthcare / Surgical Robotics / Medical Devices

Technology advantage

Proprietary 'Dual Continuum Mechanism' technology enabling snake-like surgical instruments through a single minimal incision; nearly 600 patents/applications filed globally (China, US, Europe, Canada, Japan, South Korea) as of March 2024.

How they differentiate

Focused specifically on single-port (vs multi-port) robotic surgery with snake-like flexible instruments through a single tiny incision, plus pediatric-use CE certification that competitors lack.

Main competitors

Intuitive Surgical (da Vinci), Medtronic (Hugo RAS System), CMR Surgical (Versius)

Key partnerships

IRCAD (European Clinical Excellence Center, 2025), Medtronic (strategic investor), clinical cooperation with 70+ Grade A tertiary hospitals in China, Vall d'Hebron University Hospital (first European installation).

Notable customers

70+ Grade A tertiary hospitals in China, Vall d'Hebron University Hospital (Spain, first European installation)

Major milestones

2023: NMPA approval, first approved single-port endoscopic surgical robot in China, Aug 2025: CE certification (only single-port robot certified for pediatric use), Dec 2025: $100M Series D, 2025: European Clinical Excellence Center established with IRCAD, Mar 2026: SR-ENS-660 upgrade approved by NMPA, Jul 2026: STAR Market IPO application accepted by Shanghai Stock Exchange (second attempt); first European installation at Vall d'Hebron.

Growth metrics

70+ Grade A tertiary hospital clinical partnerships in China; 3,000+ surgeries performed; ~50 innovative surgical procedures pioneered worldwide; 80+ surgical techniques developed.

Market positioning

Emerging global challenger in surgical robotics, leading single-port segment in China and expanding into high-end European market.

Geographic focus

China (domestic leader) expanding to Europe (CE certified, IRCAD partnership) and other international markets.

Patents and IP

~600 patent applications filed globally including China National Invention Patents, US Patent (US16329730), European Patent (EP3508160), Japanese Patent (JP7009480), Korean Patent (KR10-2263570), Canadian Patent (CA3035310).

About Kai Xu (Prof. Xu Kai)

Full Professor, Shanghai Jiao Tong University; research on surgical robots at Columbia University (2004); chief designer of world's first single-port laparoscopic surgical robot (IREP system, 2009); developed 'dual continuum mechanism' (2013).

Latest news about Surgerii Robotics

Surgerii Robotics raised 100 million USD in Series D funding led by Loyal Valley Capital to scale its SHURUI single-port surgical platform globally. The system uses proprietary snake-like instruments

More Robotics / Embodied AI companies

Official website: https://en.surgerii.com